Raloxifene powder, a selective estrogen receptor modulator (SERM), is a pharmaceutical raw material widely used in the manufacturing of medications primarily aimed at preventing and treating osteoporosis in postmenopausal women. It is a crystalline powder with a molecular formula of C28H27NO4S and a molecular weight of 473.6 g/mol. To satisfy the various expectations of our foreign prospects, Salispharm, a qualified distributor of pharmaceutical raw resources, offers superior products. We assure versatility in medical uses with our service, which enables many dosage forms such as pills, capsules, and injectables.
Salispharm stands out as a preferred supplier of raloxifene powder due to several key advantages:
Parameter | Value |
---|---|
Molecular Formula | C28H27NO4S |
Molecular Weight | 473.6 g/mol |
Appearance | Crystalline Powder |
Purity | ≥ 98% |
Melting Point | 143-146°C |
Storage | Store in a cool, dry place. Protect from light. |
Phosphorus in postmenopausal women is largely cautioned for avoidance and therapy with powdered raloxifene. By governing hormone receptors selectively, it operates as a challenge to the hormonal impacts on breast and endometrial tissues, while still having an endocrine disrupt affect on bone tissue. Raloxifene boosts the mineral content of bones and lowers the probability of fractures in the vertebrae among its medical benefits.
Raloxifene has also been studied for its ability to decrease the likelihood of aggressive breast cancer in postmenopausal women who are at elevated risk for the malady, as well as the hazard of breast malignancy in menopausal women who have osteoarthritis.
Osteoporosis Management: The pharmaceutical sector makes substantial use of the product in the building of illicit substances targeted to address and prevent bone loss, especially in postmenopausal women.
Breast Cancer Prevention: To show even more its diversity in oncology programs, it is additionally utilized in therapies aimed at reducing the likelihood of breast tumors in postmenopausal women.
Hormone Replacement Therapy (HRT): Menopausal women could discover that raloxifene presents a safer option with fewer negative impacts on breast and vaginal tissues as compared with standard hormonal therapy. This opportunity has been addressed.
The recommended dosage of the product for the prevention and treatment of osteoporosis in postmenopausal women is typically 60 mg orally once daily, with or without food. Following a medical provider's instructions concerning the suggested quantity and regimen is essential.
Salispharm ensures the quality and safety of our products through adherence to stringent quality standards and certification, including:
The product is securely packaged in accordance with industry best practices to ensure product integrity during transportation and storage. To enable safe and swift shipping to our clients worldwide, we make use of resilient packaging supplies and effective logistics solutions.
For inquiries or to request a quotation for raloxifene powder and other pharmaceutical raw materials, If you want to buy raloxifene powder, please feel free to reach us at sasha_slsbio@aliyun.com. We are committed to meeting your customized needs and providing exceptional service to support your business objectives.